Among them, a small molecule antagonist of TGFβR1, galunisertib, has entered phase III clinical study, developed by LLY as a new drug mainly for myelodysplastic syndrome, primary hepatocellular carcinoma, glioma, and metastatic pancreatic cancer [7]. This evidence concerns the gene TGFBR1 and central nervous system cancer.